Role of protein tyrosine phosphatases in the regulation of interferon-γ-induced macrophage nitric oxide generation:: implication of ERK pathway and AP-1 activation

被引:17
作者
Blanchette, Julie
Pouliot, Philippe
Olivier, Martin
机构
[1] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada
[2] Univ Laval, Ctr Hosp, Ctr Rech & Infectiol, Ste Foy, PQ, Canada
[3] Univ Laval, Ctr Hosp, Dept Biol Med, Ste Foy, PQ, Canada
[4] McGill Univ, Fac Med, Dept Expt Med, Montreal, PQ, Canada
[5] McGill Univ, Fac Med, Dept Microbiol, Montreal, PQ, Canada
[6] McGill Univ, Fac Med, Dept Immunol, Montreal, PQ, Canada
[7] McGill Univ, Hlth Ctr, Res Inst, Ctr Study Host Resistance, Montreal, PQ H3A 2T5, Canada
关键词
protein tyrosine kinases; transcription factors; peroxovanadiums; second messengers;
D O I
10.1189/jlb.0505252
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
NO is a potent molecule involved in the cytotoxic events mediated by macropbages (M circle divide) against microorganisms. We reported previously that inbiition of MO protein tyrosine phospbatases (PTPs) mediates a protective effect against Leishnmania infection, which was NO-dependent. Herein, we show that the PTP inhibitors of the peroxovanadium (pV) class, bpV(phen) and bpV(pic), can similarly increase murine M circle divide IFN-gamma-induced NO generation. Using various second messenger (JAK2, MEK, Erkl/Erk2, and p38) antagonists, we found that the Erk1/Erk2 pathway was the principal pathway-submitted to regulation by PTPs in the context of IFN-gamma-driven M circle divide activation and increase in NO production. We observed that bpV(phen) increases inducible NO synthase (iNOS) expression, resulting in enhanced NO production, whereas the bpV(pic) increase of NO production does not seem to result from a modulation of iNOS expression. Transcription factors STAT-lot and NF-kappa B, recoppuzed for their importance in NO generation, were not affected by the pV treatment. However, AP-1 was strongly activated by bpV(phen) but not by bpV(pic). Collectively, our results suggest that increased IFN-gamma-induced NO production, observed after bpV(phen) treatment, involves the activation of the transcription factor AP-1 by Erk1/Erk2- and stress-activated protein kinase/JNK-dependent transduction mechanisms.
引用
收藏
页码:835 / 844
页数:10
相关论文
共 72 条
[1]   Differential anti-inflammatory effects of immunosuppressive drugs:: Cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production [J].
Attur, MG ;
Patel, R ;
Thakker, G ;
Vyas, P ;
Levartovsky, D ;
Patel, P ;
Naqvi, S ;
Raza, R ;
Patel, K ;
Abramson, D ;
Bruno, G ;
Abramson, SB ;
Amin, AR .
INFLAMMATION RESEARCH, 2000, 49 (01) :20-26
[2]   Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: Specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen) [J].
Band, CJ ;
Posner, BI ;
Dumas, V ;
Contreres, JO .
MOLECULAR ENDOCRINOLOGY, 1997, 11 (13) :1899-1910
[3]  
Band CJ, 1997, J BIOL CHEM, V272, P138
[4]   Activation of HIV-1 long terminal repeat transcription and virus replication via NF-kappa B-dependent and -independent pathways by potent phosphotyrosine phosphatase inhibitors, the peroxovanadium compounds [J].
Barbeau, B ;
Bernier, R ;
Dumais, N ;
Briand, G ;
Olivier, M ;
Faure, R ;
Posner, BI ;
Tremblay, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (20) :12968-12977
[5]   IN-VIVO INSULIN MIMETIC EFFECTS OF PV COMPOUNDS - ROLE FOR TISSUE TARGETING IN DETERMINING POTENCY [J].
BEVAN, AP ;
BURGESS, JW ;
YALE, JF ;
DRAKE, PG ;
LACHANCE, D ;
BAQUIRAN, G ;
SHAVER, A ;
POSNER, BI .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1995, 268 (01) :E60-E66
[6]  
Bhat NR, 1998, J NEUROSCI, V18, P1633
[7]   Induction of activator protein 1 (AP-1) in macrophages by human immunodeficiency virus type-1 NEF is a cell-type-specific response that requires both Hck and MAPK signaling events [J].
Biggs, TE ;
Cooke, SJ ;
Barton, CH ;
Harris, MPG ;
Saksela, K ;
Mann, DA .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 290 (01) :21-35
[8]  
Blanchette J, 1999, EUR J IMMUNOL, V29, P3737, DOI 10.1002/(SICI)1521-4141(199911)29:11&lt
[9]  
3737::AID-IMMU3737&gt
[10]  
3.0.CO